Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Sigmaroc Plc | LSE:SRC | London | Ordinary Share | GB00BYX5K988 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 90.20 | 89.80 | 90.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Investment Advice | 580.29M | 13.53M | 0.0195 | 46.10 | 625.81M |
London, UK: 2 May 2007 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces that it will convene an Extraordinary General Meeting of shareholders at the offices of CMS Cameron McKenna, Mitre House, 160 Aldersgate Street, London, EC1A 4DD on Friday 25 May 2007 at 11.00am. The Notice of the Extraordinary General Meeting (including copies of the resolutions to be proposed at the meeting) has been sent to shareholders and is available on the Company's website, www.antisoma.com. A copy will shortly be available for inspection at the Document Viewing facility. Enquiries: Raymond Spencer +44 (0)20 8799 8200 Chief Financial Officer Antisoma plc Notes for Editors: Background on Antisoma Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Please visit www.antisoma.com for further information about Antisoma. - ---END OF MESSAGE--- - ---END OF MESSAGE--- Copyright � Hugin ASA 2007. All rights reserved.
1 Year Sigmaroc Chart |
1 Month Sigmaroc Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
